|
JP5977837B2
(ja)
|
2011-12-21 |
2016-08-24 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
MX373711B
(es)
|
2012-08-28 |
2020-05-08 |
Janssen Sciences Ireland Uc |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
WO2014074906A1
(en)
*
|
2012-11-09 |
2014-05-15 |
Indiana University Research And Technology Corporation |
Alternative uses for hbv assembly effectors
|
|
JP2016501531A
(ja)
|
2012-12-12 |
2016-01-21 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
ES2701749T3
(es)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
CN105102451B
(zh)
|
2013-04-03 |
2018-09-18 |
爱尔兰詹森科学公司 |
N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
SG10201710487VA
(en)
|
2013-06-17 |
2018-01-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
EP3825406A1
(en)
|
2013-06-17 |
2021-05-26 |
The Broad Institute Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
KR102244937B1
(ko)
|
2013-07-25 |
2021-04-27 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
DK3060547T3
(en)
|
2013-10-23 |
2018-01-15 |
Janssen Sciences Ireland Uc |
CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
BR112016013547A2
(pt)
|
2013-12-12 |
2017-10-03 |
Broad Inst Inc |
Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
|
|
KR20160089530A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
|
|
WO2015089462A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
EP4219699A1
(en)
|
2013-12-12 |
2023-08-02 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
EP3102225B1
(en)
|
2014-02-05 |
2020-03-25 |
Novira Therapeutics Inc. |
Combination therapy for treatment of hbv infections
|
|
US11078193B2
(en)
|
2014-02-06 |
2021-08-03 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
|
MX375407B
(es)
|
2014-06-20 |
2025-03-06 |
Univ Drexel |
Antígeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
US9884831B2
(en)
|
2015-03-19 |
2018-02-06 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
WO2016161268A1
(en)
|
2015-04-01 |
2016-10-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antviral agents
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
RU2752834C2
(ru)
|
2015-06-18 |
2021-08-09 |
Те Брод Инститьют, Инк. |
Мутации фермента crispr, уменьшающие нецелевые эффекты
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10301255B2
(en)
|
2015-07-22 |
2019-05-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017015451A1
(en)
*
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
KR101771309B1
(ko)
*
|
2015-07-24 |
2017-08-24 |
재단법인 목암생명과학연구소 |
B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물
|
|
TW201718496A
(zh)
|
2015-09-29 |
2017-06-01 |
諾維拉治療公司 |
B型肝炎抗病毒劑之晶型
|
|
WO2017136403A1
(en)
|
2016-02-02 |
2017-08-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
CN109069488B
(zh)
|
2016-03-07 |
2021-09-07 |
英安塔制药有限公司 |
乙型肝炎抗病毒剂
|
|
CN109640980A
(zh)
|
2016-04-15 |
2019-04-16 |
诺维拉治疗公司 |
包含壳体装配抑制剂的组合和方法
|
|
KR20190027814A
(ko)
|
2016-06-10 |
2019-03-15 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
|
EP3484489B1
(en)
|
2016-07-15 |
2025-06-18 |
Viracta Subsidiary, Inc. |
Hdac inhibitors for use with nk cell based therapies
|
|
RU2019120163A
(ru)
|
2016-12-13 |
2021-01-15 |
Ам Сиенсес Инк |
Фармацевтическая композиция для предупреждения или лечения гепатита B
|
|
TWI811236B
(zh)
|
2017-08-28 |
2023-08-11 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
WO2019110589A1
(en)
*
|
2017-12-04 |
2019-06-13 |
F. Hoffmann-La Roche Ag |
Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection
|
|
WO2019113175A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
WO2019143902A2
(en)
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
KR102273071B1
(ko)
*
|
2018-06-12 |
2021-07-05 |
주식회사 에이엠사이언스 |
B형 간염 예방 또는 치료용 조성물
|
|
WO2019240504A1
(en)
*
|
2018-06-12 |
2019-12-19 |
Am Sciences Co., Ltd. |
Modified oligonucleotides for inhibition of target gene expression
|
|
US10865211B2
(en)
|
2018-09-21 |
2020-12-15 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
CN112888480A
(zh)
*
|
2018-10-24 |
2021-06-01 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒疾病的新型三环化合物
|
|
US11198693B2
(en)
|
2018-11-21 |
2021-12-14 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
AR119732A1
(es)
|
2019-05-06 |
2022-01-05 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
|
|
KR20220034736A
(ko)
|
2019-05-31 |
2022-03-18 |
비락타 서브시디어리 인크. |
히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
|
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
US11472808B2
(en)
|
2019-06-04 |
2022-10-18 |
Enanta Pharmaceuticals, Inc. |
Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
EP4037706A4
(en)
*
|
2019-10-02 |
2023-09-13 |
University of Washington |
Compositions and methods for treatment of hepatitis b virus infection
|
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
EP4200419A2
(en)
*
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
|
CN112274516B
(zh)
*
|
2020-10-26 |
2022-08-05 |
中山大学附属第三医院 |
一种新型含碘抗病毒药物
|
|
IT202100005054A1
(it)
*
|
2021-03-04 |
2022-09-04 |
Azienda Ospedaliero Univ Di Parma |
Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti
|